<DOC>
	<DOCNO>NCT00418275</DOCNO>
	<brief_summary>To evaluate safety profile HTU-PA patient acute ischemic stroke .</brief_summary>
	<brief_title>Safety Study Recombinant Human Plasminogen Activator Treat Acute Ischemic Stroke .</brief_title>
	<detailed_description>Cerebrovascular disease , third lead cause death heart disease cancer develop country , overall prevalence 794 per 100,000 . In United States , estimate 400,000 patient discharge year hospital stroke . The loss patient work force extend hospitalization require recovery make serious economic impact . In Taiwan , Cerebrovascular disease second cause death .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>Subjects cerebral ischemia location produce serious measurable deficit NIHSS scale receive study medication within 5 hour onset symptom . A serious measurable deficit NIHSS define NIHSS  9  20 ( brain stem stroke , patient NIHSS &gt; 20 include ) . Subjects  18 year old , either sex . Subjects his/her legal guardian demonstrate willingness participate study comply procedure sign write informed consent . Subjects Modified Rankin Scale &gt; 1 . Onset symptom awake sleep . Intracranial bleeding detect pretreatment head computerize tomographic ( CT ) scan . Clinical presentation suggest subarachnoid hemorrhage even head CT scan normal . Head CT show evidence early infarct sign &gt; 1/3 MCA territory . Subjects generalized seizure onset stroke . Subjects blood glucose &lt; 50 mg/dl &gt; 400 mg/dl . Subjects another stroke , head trauma , cerebral hemorrhage ischemic infarction within 3 month prior study entry . Subjects significant surgery within 14 day prior study entry . Subjects history gastrointestinal urinary tract hemorrhage within 21 day prior study entry . Subjects lumbar puncture arterial puncture noncompressible site within 14 day prior study entry . Subjects know bleed diathesis . Subjects serious medical illness interfere study . Subjects platelet count &lt; 100,000/mm3 ; hematocrit &lt; 30 % . Subjects serious medical illness interfere study . Subjects aPTT PT &gt; upper normal limit . Subjects uncontrolled hypertension ( &gt; 180 mmHg systolic &gt; 110 mmHg diastolic ) without additional antihypertensive medication screen visit . Subjects recent transmural myocardial infarction evidence pericarditis within 3 week prior enrollment . Subjects intracranial neoplasm , arteriovenous malformation , aneurysm . Subjects hemostasis defect include secondary severe hepatic renal disease . Subjects history drug alcohol abuse within 1 year prior study entry . Subjects significant hepatic dysfunction ( SGOT/SGPT  3 x upper normal limit ) . Subjects serum creatinine level  2 x upper normal limit renal dialysis . Subjects administration investigational drug within 30 day prior study entry . Woman pregnant nursing . Subjects use thrombolytic ( streptokinase , tissue plasminogen activator , urokinase , anisoylated plasminogen streptokinase activator complex , anticoagulant ) . Subjects severe cardiac disease ( New York Heart Association Functional Classification III IV ) . Subjects history cancer except inactive nonmelanoma skin cancer , situ carcinoma cervix , cancer patient ’ disease free 5 year . Subjects clinically significant deviation normal physical examination , investigator judgment , interfere study evaluation affect subject safety . Subjects history lupus . Vasculitis cause ischemic stroke . Subjects enrol study previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Cerebrovascular Stroke</keyword>
</DOC>